Clinical Trials

672 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT07227597 2026-05-26

MK-6070-003

170 enrolled

Phase 1 Active not recruiting

Small Cell Lung Cancer Extensive Stage

NCT02632708 2026-05-22

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

153 enrolled

Leukemia, Myeloid, Acute

NCT06564844 2026-05-22

TROPION-Lung12

25 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT07005128 2026-05-22

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT07155174 2026-05-18

SEZanne

180 enrolled

Small Cell Lung Carcinoma

NCT04380636 2026-05-15

MK-7339-012

870 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07472517 2026-05-12

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

670 enrolled

Small Cell Lung Carcinoma

NCT06230224 2026-05-11

OLYMPIA-4

216 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06646276 2026-05-11

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

530 enrolled

Small Cell Lung Carcinoma

NCT07296809 2026-05-08

SKB500 Combinations in Patients With Small Cell Lung Cancer

80 enrolled

Small Cell Lung Carcinoma

NCT03182244 2026-05-05

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

276 enrolled 41 charts

Leukemia, Myeloid, Acute

NCT05533775 2026-05-04

iMATRIX GLO

65 enrolled

Recurrence

NCT05815160 2026-05-04

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Terminated

34 enrolled

Recurrence, Small Cell Lung Carcinoma

NCT04702880 2026-04-29

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Phase 2 Completed

135 enrolled

Small Cell Lung Carcinoma

NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Phase 2 Terminated

40 enrolled

Extensive Stage Small Cell Lung Cancer

NCT03591510 2026-04-27

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT04745689 2026-04-24

TAZMAN

31 enrolled 15 charts

Small Cell Lung Carcinoma

NCT03043872 2026-04-22

CASPIAN

987 enrolled 42 charts 1 FDA

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07502300 2026-04-20

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

562 enrolled

Small Cell Lung Carcinoma

NCT06449209 2026-04-17

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

110 enrolled

Small Cell Lung Carcinoma

NCT06741644 2026-04-15

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

660 enrolled

Phase 1 Active not recruiting

Advanced Solid Tumors

NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

21 enrolled

SCLC,Extensive Stage

NCT04256421 2026-04-03

SKYSCRAPER-02

Phase 3 Completed

490 enrolled 33 charts

Phase 1/2 Active not recruiting

Small Cell Lung Carcinoma

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

65 enrolled

Phase 1/2 Active not recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

24 enrolled

Phase 1/2 Not yet recruiting

Extensive Stage Small Cell Lung Cancer

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

596 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05091567 2026-03-10

IMforte

660 enrolled 23 charts 1 FDA

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

184 enrolled

Bites and Stings, Lung Neoplasms

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Lymphoid

Hodgkin Disease

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04665856 2026-02-13

SKYSCRAPER-02C

123 enrolled 26 charts

Small Cell Lung Carcinoma

NCT06712355 2026-02-13

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

621 enrolled

Phase 1/2 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT07381829 2026-02-02

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

Phase 1 Recruiting

328 enrolled

Advanced Solid Tumor Cancer

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

167 enrolled

Phase 2/3 Active not recruiting

Leukemia, Myeloid, Acute

NCT06105619 2026-01-20

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

84 enrolled

CNS

Glioblastoma

NCT07268040 2026-01-12

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

400 enrolled

Malignant Solid Tumors

NCT04063163 2025-12-09

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

Phase 3 Completed

585 enrolled 14 charts

371 enrolled 36 charts 2 FDA

Small Cell Lung Carcinoma

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase 3 Completed

Leukemia, Myeloid, Acute

NCT05364424 2025-12-01

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Phase 1 Completed

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07245446 2025-11-24

A Study of Ivonescimab in First-Line ES-SCLC

180 enrolled

Small Cell Lung Carcinoma

NCT02964013 2025-10-14

KEYVIBE-001

Phase 1 Completed

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

LymphoidOther hematologic neoplasm

Small Cell Lung Carcinoma

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04047862 2025-08-22

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1 Completed

446 enrolled 49 charts

Locally Advanced and Metastatic Solid Tumors

NCT05298423 2025-08-01

KEYVIBE-006

611 enrolled